christopher charles giangreco – Trademark Portfolio
Entity Type: 01
christopher charles giangreco holds 20 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 32 (Light Beverages) — 11 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 5 Nice Classification classes. Currently, 0 trademarks are registered and 10 are pending. The owner is based in bayside, NY.
3929 221 street
bayside, NY 11361
Showing of trademarks Trademarks
Trademark Classifications
christopher charles giangreco's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does christopher charles giangreco have?
christopher charles giangreco has 20 U.S. trademarks filed with the USPTO. Of these, 10 pending, 10 abandoned.
What trademark classes does christopher charles giangreco file in?
christopher charles giangreco files trademarks across 5 Nice Classification classes. The most active classes are Class 32 (Light Beverages), Class 5 (Pharmaceuticals), Class 31 (Natural Agricultural Products), Class 30 (Staple Foods), Class 42 (Computer & Scientific). Class 32 covers beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages.
What is christopher charles giangreco's trademark registration success rate?
christopher charles giangreco has a 0% trademark registration rate, with 0 out of 10 resolved applications resulting in successful registration. Currently, 10 applications are pending review.